Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine nasal spray versus quetiapine XR in treatment-resistant major depressive disorder
2019-002992-33Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in major depressive disorder (MDD) comparing Esketamine nasal spray + continuing SSRI/SNRI with Quetiapine XR + continuing SSRI/SNRI (2 arms). Started Apr 2020; status: completed.
02
Drugs
esketaminequetiapine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2019-002992-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002992-33.